Guidance

Meningococcal disease: guidance on public health management

Advice for health protection professionals on the management of meningococcal disease in the UK.

From:
UK Health Security Agency
Published
1 March 2012
Last updated
12 November 2024 鈥� See all updates

Documents

Ref: GOV-17581

PDF, 600 KB, 60 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 19.2 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 17 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 15.8 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 16.6 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 16.1 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 22.6 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 22.9 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ref: GOV-17178

MS Word Document, 22.4 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Management, guidance and control measures from UK Health Security Agency鈥檚 Vaccine Preventable Invasive Bacterial Infections Forum.

This guidance on the public health management of individual cases and clusters of invasive meningococcal disease (IMD) includes information on:

  • epidemiology of IMD
  • vaccination programmes
  • laboratory investigations of suspected cases
  • public health actions after a case
  • chemoprophylaxis in healthcare settings
  • clusters and management

Updates to this page

Published 1 March 2012
Last updated 12 November 2024 show all updates

  1. Updated guidance - see change history.

  2. Updated guidance - see change history.

  3. Updated guidance and letter templates.

  4. Added revised guidance document (see change history on page 5) and communication templates document.

  5. Added revised communication templates.

  6. Published new combined guidance on the public health management of meningococcal disease.

  7. First published.

Sign up for emails or print this page

Related content